Gilead Sciences Inc

GILD

NASDAQ. Currency in USD

87.99 -1.05 ( -1.17% )

Real time prices: December 05

Market Cap.
110.37B
Beta (5Y monthly)
0.44
Price/Earnings
13.58
EPS (TTM)
6.29
Forward Dividend
2.92 (3.40%)
Ex-Dividend Date
Dec 15, 2022
Volume
6.73M
1y Target Est.
81.75
Day's Range
86.55
-
89.07
52 Week's Range
57.16
-
89.07

Historical Summary

Performance
EPS growth
Share Buybacks

About Gilead Sciences Inc

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.gilead.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
1.25B
Employees
14400
Address
333 Lakeside Drive, Foster City, CA, United States, 94404
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Latest news

GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe

GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision...
By Zacks Investment Research - 4 hours ago

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector...
By Zacks Investment Research - 5 hours ago

Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take...
By Zacks Investment Research - 3 days ago

Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global...
By Zacks Investment Research - 3 days ago

Expert Ratings for Gilead Sciences
Expert Ratings for Gilead Sciences

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat...
By Benzinga - 4 days ago

Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?
Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 4 days ago